Drugmaker Nostrum and Its CEO
Outcome
OIG enforcement action against Drugmaker Nostrum and Its CEO for false claims. Penalty: $50 million.
Details
Drugmaker Nostrum and Its CEO — OIG Enforcement (2026)
OIG took enforcement action against Drugmaker Nostrum and Its CEO in MO in 2026 involving false claims violations in the Healthcare General sector.
Penalty: $50 million
Violation types: False Claims
Entity type: Healthcare Provider
Penalty type: Settlement
Location: MO
Source: Drugmaker Nostrum and Its CEO Agree to Pay Up to $50 Million to Settle False Claims Act Claims for Underpaying Rebates Owed Under Medicaid Drug Rebate Program
How Crucible Prevents This
Crucible's billing compliance controls enforce documentation-to-claims reconciliation, requiring clinical attestation before claims submission and flagging billing patterns that deviate from documented care delivery.
Don't let this happen to your organization. See how Crucible works.
See How Crucible Works